The new national medical insurance list will be implemented starting today, benefiting patients with three innovative drugs from SKB BIO-B (06990).

It is understood that on January 1st, the "National Basic Medical Insurance, Maternity Insurance, Work Injury Insurance Drug List and Commercial Health Insurance Innovative Drug List (2025)" was officially implemented. In this new list, three innovative drugs developed by SKB BIO-B (06990) - Lucanushatuzumab (Jiatailai), Situximab N01 (Datailai), and Tagolimusimab (Ketailai) were successfully included. It is reported that for patients with advanced triple-negative breast cancer and non-small cell lung cancer who have failed EGFR-TKI treatment, traditional treatment methods often have little effect. As the first domestically produced ADC (Antibody Drug Conjugate) developed independently by Kebotai, Lucanushatuzumab was officially approved in November 2024 for the treatment of unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) that has received at least two prior systemic treatments (with at least one targeting late stage or metastatic stage). It has opened up a new treatment pattern for second-line and above advanced TNBC patients. In March 2025, the drug was successfully approved for a second indication, for the treatment of EGFR mutation-positive locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) that has progressed after EGFR-TKI therapy and platinum-containing chemotherapy, filling a gap in the field of late-line therapy. The inclusion of these three drugs in medical insurance not only reduces the high treatment costs in the past, but also effectively relieves patients' economic pressures through the medical insurance reimbursement mechanism, making this "hope for life" truly accessible. In response to the unmet clinical needs and the reduction of treatment costs, Dr. Ge Junyou, General Manager and CEO of Kebotai, stated, "When you know that your innovative research results may change the treatment pattern of a disease field, and can fill a current unmet treatment area, that sense of mission surpasses any commercial consideration. Although similar treatment products are already in the medical insurance directory, we are willing to promote domestic alternatives at more affordable prices to prevent patients from falling into poverty due to illness or returning to poverty due to illness."